Fig 3. IL-6 signaling does not affect BCR revision, but controls MZL phenotype in KSHV-infected cultures.

(A) Naïve B lymphocyte cultures were infected with KSHV or Mock infected and treated with PBS (Control), IL6 neutralizing antibody at 200ng/ml or gp130 neutralizing antibody at 2μg/ml. At 6 days post-infection, cells were analyzed by FCM and subsets were gated as in Fig 2D. Results were verified in two independent experiments with two tonsil specimens. (B) Aggregate data for 10 individual observations from 6 independent experiments correlating the induction of IL6 (KSHV/Mock) from Fig 2A with the MZL (IgD+CD27+) population in the same sample at the same timepoint. Log regression was performed in R software using least means method (r² = 0.82, p = 0.0003) and gray shading represents a 95% confidence interval. (C) Mock or KSHV infected naïve B lymphocytes were treated with IL-6 or gp130 antibodies and analyzed as in Fig 1B. Plots shown are from a singlet/viable/CD19+CD38low gating hierarchy in a representative experiment and results were verified in two independent experiments with two tonsil specimens.